CD274 and neoplasm: Here, we aimed to evaluate the prognosis, efficacy and safety associated with pembrolizumab in such settings.<h4>Methods</h4>In this single-institution retrospective study conducted from May 2017 to October 2019, pembrolizumab was administered to 72 Japanese patients with treatment-naïve advanced NSCLC with PD-L1 tumor proportion score (TPS) ≥50%.